KR101627382B1 - 항암 경구 제제 - Google Patents

항암 경구 제제 Download PDF

Info

Publication number
KR101627382B1
KR101627382B1 KR1020117003208A KR20117003208A KR101627382B1 KR 101627382 B1 KR101627382 B1 KR 101627382B1 KR 1020117003208 A KR1020117003208 A KR 1020117003208A KR 20117003208 A KR20117003208 A KR 20117003208A KR 101627382 B1 KR101627382 B1 KR 101627382B1
Authority
KR
South Korea
Prior art keywords
peg
preparation according
pharmaceutical preparation
tpgs
transcutol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117003208A
Other languages
English (en)
Korean (ko)
Other versions
KR20110038135A (ko
Inventor
텡쾅 예
치웅-통 첸
유-쉥 차오
Original Assignee
내셔날 헬스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내셔날 헬스 리서치 인스티튜트 filed Critical 내셔날 헬스 리서치 인스티튜트
Publication of KR20110038135A publication Critical patent/KR20110038135A/ko
Application granted granted Critical
Publication of KR101627382B1 publication Critical patent/KR101627382B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020117003208A 2008-07-11 2009-07-10 항암 경구 제제 Expired - Fee Related KR101627382B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/171,515 US8026271B2 (en) 2008-07-11 2008-07-11 Formulations of indol-3-yl-2-oxoacetamide compounds
US12/171,515 2008-07-11

Publications (2)

Publication Number Publication Date
KR20110038135A KR20110038135A (ko) 2011-04-13
KR101627382B1 true KR101627382B1 (ko) 2016-06-03

Family

ID=41505721

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117003208A Expired - Fee Related KR101627382B1 (ko) 2008-07-11 2009-07-10 항암 경구 제제

Country Status (8)

Country Link
US (1) US8026271B2 (enExample)
EP (1) EP2310363B1 (enExample)
JP (1) JP5596680B2 (enExample)
KR (1) KR101627382B1 (enExample)
CN (1) CN102159541B (enExample)
ES (1) ES2426599T3 (enExample)
TW (1) TWI384984B (enExample)
WO (1) WO2010006234A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
HRP20140754T2 (hr) 2009-06-29 2015-07-17 Incyte Corporation Pirimidinoni kao inhibitori pi3k
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US9556166B2 (en) * 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
LT3196202T (lt) 2011-09-02 2019-07-10 Incyte Holdings Corporation Heterociklilaminai, kaip pi3k slopikliai
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN117736209A (zh) 2015-02-27 2024-03-22 因赛特控股公司 Pi3k抑制剂的盐及其制备方法
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520772A (ja) 1999-06-11 2003-07-08 アボット・ラボラトリーズ 脂質調節剤を含む新規製剤
US20030181482A1 (en) 2001-12-06 2003-09-25 Chiung-Tong Chen Novel compounds and methods of use thereof
EP2310363B1 (en) 2008-07-11 2013-06-05 National Health Research Institutes Anticancer oral formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP1817012A2 (en) * 2004-11-24 2007-08-15 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US20060134204A1 (en) * 2004-12-21 2006-06-22 Wong Patrick S Complexes made using low solubility drugs
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2008066899A2 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
HRP20120960T1 (hr) * 2007-01-16 2012-12-31 Bipar Sciences, Inc. Formulacije za lijeäśenje raka

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520772A (ja) 1999-06-11 2003-07-08 アボット・ラボラトリーズ 脂質調節剤を含む新規製剤
US20030181482A1 (en) 2001-12-06 2003-09-25 Chiung-Tong Chen Novel compounds and methods of use thereof
EP2310363B1 (en) 2008-07-11 2013-06-05 National Health Research Institutes Anticancer oral formulation

Also Published As

Publication number Publication date
ES2426599T3 (es) 2013-10-24
EP2310363A2 (en) 2011-04-20
JP5596680B2 (ja) 2014-09-24
US8026271B2 (en) 2011-09-27
CN102159541B (zh) 2014-06-04
EP2310363A4 (en) 2012-03-28
EP2310363B1 (en) 2013-06-05
CN102159541A (zh) 2011-08-17
WO2010006234A3 (en) 2010-04-08
KR20110038135A (ko) 2011-04-13
TWI384984B (zh) 2013-02-11
TW201002319A (en) 2010-01-16
WO2010006234A2 (en) 2010-01-14
US20100010059A1 (en) 2010-01-14
JP2011527704A (ja) 2011-11-04

Similar Documents

Publication Publication Date Title
KR101627382B1 (ko) 항암 경구 제제
TWI869913B (zh) 吡啶并[4,3-d]嘧啶化合物
JP7673041B2 (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
CN111225665A (zh) 大环免疫调节剂
AU2020310120B2 (en) Formulations of RBP4 inhibitors and methods of use
JP6742343B2 (ja) ２環性複素環化合物
WO2018086446A1 (zh) 具有穿过血脑屏障能力的取代的喹唑啉化合物
CN114989182A (zh) 脂质化合物、包含其的组合物及应用
CN106478502B (zh) 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
WO2022171115A1 (zh) 用于adc制备的喜树碱衍生物
CN110325536A (zh) Janus激酶抑制剂的晶体形式
CN115160227A (zh) R-或s-2-(1-乙酰氧正戊基)苯甲酸与4-氟-依达拉奉的杂合物及其制备与应用
JPWO2021007435A5 (enExample)
TW202330015A (zh) 作為治療劑之肽微管蛋白抑制劑之肽結合物
KR20080096832A (ko) 캄토테신 유도체 및 그의 용도
ES2906048T3 (es) Nuevas formas de sal cristalinas de 3-(1,2,4-triazolo[4,3-a]piridin-3-iletinil)-4-metil-N-(4-((4-metilpiperazin-1-il)metil)-3-trifluorometilfenil)benzamida para aplicación médica
JP5620046B2 (ja) テモゾロマイドエステルよりなる医薬組成物
CN114736214A (zh) 一种倍半萜衍生物、其药物组合物及其制备方法和用途
CN107304188A (zh) 一种氘代激酶选择性抑制剂及其应用
CN114105977A (zh) 雌激素受体调节剂化合物及其用途
WO2015074605A1 (zh) 一种紫杉烷类化合物、其制备方法和用途
HK1158184A (en) Anticancer oral formulation
WO2019196622A1 (zh) 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN109280054A (zh) 氘代3-奎宁环酮类化合物、制备方法及用途
KR20250100539A (ko) 피리도[4,3-d]피리미딘 화합물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190531

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190531

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000